Nivolumab, a programmed death receptor-1 (PD-1) immune checkpoint inhibitor, is used to treat various types of cancers such as melanoma, non-small cell lung cancer, and renal cell carcinoma, among others [1]. The standard schedule for nivolumab administration may vary depending on the specific cancer type, the patient's overall health, and other factors. However, some general guidelines can be provided based on the available information.

For most indications, nivolumab is administered intravenously over 30 minutes, typically every 2 weeks (known as a 2-week cycle) [1][2]. For example, for the treatment of metastatic melanoma, nivolumab is given at a dose of 240 mg every 2 weeks until disease progression or unacceptable toxicity [1]. Similarly, for non-small cell lung cancer, nivolumab is administered at a dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression [1].

It is important to note that the dosage and schedule for nivolumab may be adjusted based on individual patient characteristics, such as renal or hepatic impairment, and the presence of adverse reactions [1]. Additionally, nivolumab may be used in combination with other cancer therapies, which could affect the dosage and administration schedule [1].

In terms of drug patents, Nivolumab was first approved by the FDA in December 2014 and its patent expired in October 2020 [3]. However, the drug's formulation and method of use may still be protected by additional patents [3]. For the most up-to-date information on nivolumab patents, it is recommended to consult resources such as DrugPatentWatch.com [3].

In summary, the standard schedule for nivolumab administration is typically every 2 weeks, but the specific dosage and frequency may vary depending on the cancer type and individual patient factors. It is crucial for healthcare providers to closely monitor patients receiving nivolumab for adverse reactions and adjust the treatment plan accordingly.

Sources:

1. National Comprehensive Cancer Network. Nivolumab. <https://www.nccn.org/professionals/physician_gls/pdf/nivolumab.pdf>
2. Bristol Myers Squibb. Opdivo (nivolumab) Prescribing Information. <https://packageinserts.bms.com/pi/pi_opdivo.pdf>
3. DrugPatentWatch. Nivolumab. <https://www.drugpatentwatch.com/drugs/nivolumab>